Business Context and Reporting Period
Company: Nukkleus Inc. (NUKK)
Filing Type: Form 8-K (Current Report)
Date of Report: December 15, 2024
Event: Entry into a Material Definitive Agreement to acquire a controlling 51% interest in Star 26 Capital Inc. ("Star"), a defense acquisition company. Star holds a 95% stake in B. Rimon Agencies Ltd. ("Rimon"), an Israeli supplier of generators for "Iron Dome" launchers and tactical defense vehicles.
Key Financial Metrics and Transaction Terms
Acquisition Consideration (51% Stake):
- Total Value: $15,000,000
- Cash Component: Minimum $5,000,000
- Debt Component: Promissory note for the remaining balance, maturing 12 months post-closing.
- Equity Component: 2,385,170 shares of Nukkleus common stock.
- Warrant Component: Five-year warrant to purchase 6,907,859 shares at $1.50 per share.
Call Option (Remaining 49% Stake):
- Option Exercise Price: $16,084,250
- Payment Structure: $3,000,000 cash, $3,000,000 promissory note (8% interest, due in 6 months), 2,385,170 shares of common stock, and a five-year warrant to purchase 5,109,789 shares at $1.50 per share.
Liquidity and Debt: The filing does not provide current cash balances, total debt, or liquidity metrics for Nukkleus Inc. prior to this transaction.
Material Changes and Operational Impact
Strategic Shift: The transaction marks a significant expansion into the global defense sector, specifically targeting growth in defense acquisition and supply chain integration.
Target Operations: Rimon operates two primary lines: (1) distribution of generators, masts, and lightning solutions; and (2) engineering and production of tactical vehicles (reconnaissance, command/control, firefighting, and satellite platforms) for defense forces and intelligence agencies.
Management Overlap: Menachem Shalom, Nukkleus CEO and director, is also the controlling shareholder and CEO of Star.
Guidance, Risks, and Contingencies
Closing Conditions: The transaction is subject to regulatory approvals, third-party consents, a fairness opinion, and shareholder approval required by Nasdaq listing rules.
Delisting Contingency: If Nukkleus common stock is delisted from Nasdaq within 12 months of closing, Star has the right to require Nukkleus to exchange the Investment Note for all Star shares held by Nukkleus. In this scenario, the Call Option is automatically cancelled, Star retains cash payments made, and Nukkleus retains an equity interest in Star equivalent to the cash paid.
Outlook: Management anticipates growth and transformation within the global defense sector and plans to integrate Star's operations into its existing structure.
Investor Verification Checklist
- Shareholder Approval: Verify the outcome of the required shareholder vote for Nasdaq compliance.
- Regulatory Clearance: Confirm receipt of necessary regulatory approvals and third-party consents for the cross-border defense acquisition.
- Funding Sources: Determine the source of the minimum $5,000,000 cash payment and the $3,000,000 cash portion of the option exercise price.
- Debt Covenants: Review the terms of the promissory notes (12-month and 6-month maturities) for interest rates and repayment conditions.
- Delisting Risk: Assess the current status of Nukkleus's Nasdaq listing compliance to evaluate the risk of the delisting contingency clause being triggered.